Page last updated: 2024-12-06
sulforidazine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
sulforidazine: structure in Merck [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 31765 |
| CHEMBL ID | 2107268 |
| CHEBI ID | 135644 |
| SCHEMBL ID | 145025 |
| MeSH ID | M0120916 |
Synonyms (56)
| Synonym |
|---|
| tpn 12 |
| brn 1230366 |
| sulforidazinum [inn-latin] |
| sulforidazina [inn-spanish] |
| 2-methylsulfonyl-10-(2-(1-methyl-2-piperidyl)ethyl)phenothiazin |
| psychoson |
| sulforidazine |
| phenothiazine, 10-(2-(1-methyl-2-piperidyl)ethyl)-2-methylsulfonyl- |
| tpn-12 |
| imagotan |
| sulforidazine [inn:dcf] |
| 10-(2-(1-methyl-2-piperidyl)ethyl)-2-methylsulfonylphenothiazine |
| inofal |
| solforidazina [dcit] |
| einecs 238-818-7 |
| CHEBI:135644 |
| L000789 |
| 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfonylphenothiazine |
| sulforidazina |
| 14759-06-9 |
| unii-b7599i244x |
| b7599i244x , |
| solforidazina |
| sulforidazinum |
| cas_14759-06-9 |
| nsc_31765 |
| bdbm86723 |
| thioridazine-2-sulfone |
| thioridazine sulphone |
| thioridazine sulfone |
| CHEMBL2107268 |
| FT-0675190 |
| (+/-)-thioridazine-2-sulfone |
| thioridazine 2-sulfone |
| thioridazine hydrochloride impurity e [ep impurity] |
| 10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfonyl)- |
| 103827-31-2 |
| thioridazine impurity e [ep impurity] |
| 2-methylsulfonyl-10-(2-(1-methyl-2-piperidyl)ethyl)phenothiazine |
| sulforidazine [who-dd] |
| phenothiazine, 10-(2-(1-methyl-2-piperidyl)ethyl)-2-(methylsulfonyl)- |
| sulforidazine [mi] |
| sulforidazine [inn] |
| sulforidazine [mart.] |
| 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfonyl)-10h-phenothiazine |
| SCHEMBL145025 |
| 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylsulfonyl)-10h-phenothiazine # |
| FLGCRGJDQJIJAW-UHFFFAOYSA-N |
| 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-methylsulfonylphenothiazine |
| 10h-phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylsulfonyl)- |
| 2-methylsulfonyl-10-[2-(1-methyl-2-piperidyl)ethyl]phenothiazine |
| 2-methanesulfonyl-10-[2-(1-methylpiperidin-2-yl)ethyl]-10h-phenothiazine |
| AKOS030239787 |
| J-008369 |
| Q7636215 |
| DTXSID30864531 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 h) was administered to all the volunteers to investigate the effect of a slow rate of dosage input on the pharmacokinetic parameters of this drug." | ( Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study. Chakraborty, BS; Choc, MG; Hawes, EM; Hubbard, JW; Korchinski, ED; McKay, G; Midha, KK; Robinson, WT, 1989) | 0.28 |
| "The relationship between chronic oral dosage with a long-acting formulation of propranolol and plasma propranolol levels 22 to 23 hours later is described in 12 adult male patients with organic brain disease." | ( Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations. Greendyke, RM; Kanter, DR, 1987) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| phenothiazines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (22)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 13 (59.09) | 18.7374 |
| 1990's | 7 (31.82) | 18.2507 |
| 2000's | 2 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 18.39
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.39) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (12.50%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||